Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
All Main/Primary objectives are MK-4305 high dose compared to placebo, as measured by change from baseline: Maintenance- 1. Mean subjective total sleep time (sTSTm) at Month 1 2. Wakefulness after persistent sleep onset (WASO) by PSG at Month 1 3. Mean subjective total sleep time (sTSTm) at Month 3 4. Wakefulness after persistent sleep onset (WASO) by PSG at Month 3 Onset- 5. Mean subjective time to sleep onset (sTSOm) at Month 1 6. Latency to onset of persistent sleep (LPS) by PSG at Month 1 7. Mean subjective time to sleep onset (sTSOm) at Month 3 8. Latency to onset of persistent sleep (LPS) by PSG at Month 3 Safety- 9. Safety and tolerability of MK-4305 for up to 3 months of treatment
Critère d'inclusion
- Primary Insomnia